Skip Nav Destination
Close Modal
Update search
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Journal
Article Type
Date
Availability
1-9 of 9
Keywords: Epirubicin
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Sort by
Journal Articles
Subject Area:
Oncology
M. Rummel, M. Schenk, Ch. Renner, A. Knuth, K. Josten, U. Reinhardt, B. Rendenbach, H.-J. Pielken, C. Wojatschek, E. Lengfelder, P.S. Mitrou, D. Hoelzer, L. Bergmann
Journal:
Onkologie
Onkologie (1997) 20 (4): 328–331.
Published Online: 13 May 2009
... was to evaluate the rate and duration of remissions and to examine toxicity and immunosuppressive effects of fludarabine and epirubicin in treatment of CLL in stages Binet B and C as first-line therapy or in first relapse. Patients and Methods: 39 patients with CLL in stages Binet B or C or with leukemic...
Journal Articles
Subject Area:
Oncology
N. Tsavaris, N. Mylonakis, Ch. Bacoyiannis, G. Papastratis, M. Katsikas, V. Papadimitrakopoulou, A. Macheras, A. Stamelou, P. Kosmidis
Journal:
Onkologie
Onkologie (1995) 18 (4): 346–350.
Published Online: 11 May 2009
...N. Tsavaris; N. Mylonakis; Ch. Bacoyiannis; G. Papastratis; M. Katsikas; V. Papadimitrakopoulou; A. Macheras; A. Stamelou; P. Kosmidis Background : The combination of 5-fluorouracil (5-FU) and folinic acid (FA) has demonstrated activity in most gastrointestinal tumors. The addition of epirubicin...
Journal Articles
Subject Area:
Oncology
Journal:
Onkologie
Onkologie (1992) 15 (3): 198–204.
Published Online: 29 April 2009
.... Comparative studies show that generally anthracyclines with lower potential cardiotoxicity are clinically less effective. Epirubicin and idarubicin are either equally or more effective than doxorubicin or daunorubicin, respectively and at the same time less cardiotoxic. Anthracyclines Cardiotoxicity...
Journal Articles
Subject Area:
Oncology
Journal:
Onkologie
Onkologie (1990) 13 (4): 313–315.
Published Online: 28 April 2009
...N.W. Marschner; M. Adler; F. Jaenicke; U. Albrecht; G.A. Nagel 40 Patientinnen mit metastasiertem Mammakarzinom, welche zytostatisch mit Epirubicin ( > 50mg/m 2 , Tag 1) und Cyclophosphamid ( > 500mg/m 2 , Tag 1) behandelt wurden, erhielten eine antiemetische Therapie mit Ondansetron 3×8mg...
Journal Articles
Subject Area:
Oncology
Journal:
Onkologie
Onkologie (1986) 9 (Suppl. 1): 11–12.
Published Online: 24 April 2009
...D. Christmann Epirubicin wurde beim metastasierten Mammakarzinom in Kombination mit Vincristin und Cyclophosphamid (VEC) bei 14 Patientinnen und beim fortgeschrittenen Ovarialkarzinom in Kombination mit Cisplatin und Cyclophosphamid (PEC) bei 12 Patientinnen eingesetzt. Bei der Behandlung des...
Journal Articles
Subject Area:
Oncology
Journal:
Onkologie
Onkologie (1986) 9 (Suppl. 1): 21–23.
Published Online: 24 April 2009
...J.A. Wils A review of the activity of epirubicin in advanced gastrointestinal tumors is presented. In gastric cancer epirubicin has comparable activity to its parent compound doxorubicin with less toxicity. Epirubicin seems particularly active in pancreatic cancer as shown by the results of two...
Journal Articles
Subject Area:
Oncology
Journal:
Onkologie
Onkologie (1986) 9 (Suppl. 1): 8–10.
Published Online: 24 April 2009
...R. Keiling; P.P. Armand; P. Hurteloup; P. Cappelaere 239 Patientinnen waren auswertbar: 116 im FAC-Arm, 123 im FEC-Arm. Kein Unterschied in der Wirksamkeit zwischen der Adriamycin- und der Epirubicin-Kombination mit äquimolarer Dosis (50 mg): 52 ± 9% vs 49 ± 9% CR und PR, gleiche Dauer der Response...
Journal Articles
Subject Area:
Oncology
Journal:
Onkologie
Onkologie (1986) 9 (Suppl. 1): 14–20.
Published Online: 24 April 2009
...P. Drings; H. Bülzebruck; D. Hruska; H.G. Manke; G. Schuler 61 Patienten mit unbehandeltem kleinzelligem Bronchialkarzinom wurden mit der Kombination Epirubicin 70 mg/m 2 , Cyclophosphamid 1000 mg/m 2 und Vincristin 2 mg (Gesamtdosis) in Abständen von 3 Wochen behandelt. Das Durchschnittsalter der...
Journal Articles
Subject Area:
Oncology
Journal:
Onkologie
Onkologie (1986) 9 (Suppl. 1): 3–7.
Published Online: 24 April 2009
.... Epirubicin, ein neues Anthrazyklinderivat und Analog von Doxorubicin – Adriamycin (die Substanz mit der höchsten Monoaktivität beim Mammakarzinom) zeigt die gleiche hohe Aktivität bei geringerer Nebenwirkungsrate. Komplette und partielle Remissionen konnten in 33 % bei 313 Patientinnen mit metastasiertem...